Enhancement of Solubility and Dissolution Rate of Lacidipine Solid Dispersion Technique by Solvent Evaporation Method

Vankudavath Manthru Naik[1*], Prof (Dr)Chennu M MPrasada Rao[2]

[1]Research Scholar, School of Pharmacy, Raffles University, Neemrana-301705
[2]Professor, School of Pharmacy, Raffles University, Neemrana-301705

Email: manthrunaik970@gmail.com, chennuprasad12@gmail.com

ArticleInfo

ABSTRACT:

The present study was aimed in developing the solid dispersion studies of combination of the polymers like PEG 6000: PEG 4000 prepared by solvent evaporation technique with ratio of Drug and polymer ratio was 1:1:1. The Lacidipine solid dispersion were evaluated for physicochemical characteristics like drug content and in vitro drug release studies. Form FTIR studies, it concluded that there was no chemical interaction between the drugs and polymers like PEG 6000 and PEG 4000. it can provide promising way to enhance its solubility and dissolution rate. The compatibility of the drug and excipients was confirmed by DSV and XRD analysis which clearly compatibility of the polymer and drug. The optimized formulation F1 was Compared with the marketed formulation the F1 shows the In vitro drug release at 99.87% at 140 min. based on the mathematical models, the concluded that formulation F1, the regression value found to be 0.9906 fitted with Higuchi model followsFickian diffusion and suggests that drug release occurs through diffusion through dispersed vesicles.

Keywords: Solid Dispersion Technique, Polymers, Solubility, Dissolution Rate, Solvent Evaporation Method, Drug Release

1.   Introduction

The term solid dispersion refers to a group of solid products consisting of atleast two different components, generally a hydrophilic matrix and a hydrophobicdrug. The matrix can be either crystalline or amorphous. The drug can be dispersedmolecularly, in amorphous particles (clusters) or in crystalline particles. Therefore,based on their molecular arrangement, six different types of solid dispersions can bedistinguished. Moreover, certain combinations can be encountered, i.e. in the samesample; some molecules are present in clusters while some are molecularly dispersed.Moreover, not the preparation   method   but   the   molecular   arrangement   governs thepropertiesofsoliddispersions.[1]

Fairly soluble drugs in gastrointestinal media exhibit complete oral absorption,and thus good bioavailability. About 40% of drugs are not soluble in water in practiceandthereforeareslowlyabsorbed,whichresultsininsufficientandunevenbioavailabilit yandGItoxicity.Thus,mostexigentphaseofdrugdevelopmentpractice   particularlyfororal dosageformsis   the   enhancementof   drugsolubilitythereby   its   oral   bioavailability. Bioavailability refers to the limit of therapeuticallyactive drug that approaches the systemic   circulation   and   thus,   is   available   at   the   site   ofaction.There   are tworeasonsproposedforpooraqueoussolubilityofdrugs [2]

 i.   Highlipophilicity
ii.   Stronginfermolecularforceswhichcausetheinsolubilizationofdrugs.

Various approaches have been proposed to enhance solubilisation of poorlywater soluble drugs for the improvement of their bioavailabilitycommonly used fordrug solubilization includes   micronization,   chemical   modification,   pH adjustment,soliddispersion,complexation,co-solvency,micellarsolubilisationandhydrotropy.[3]

Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure. Compared to other dihydropyridine calcium antagonists, Lacidipine exhibits a greater antioxidant activity which may confer potentially beneficial antiatherosclerosis effects. It having Chemical formulae $C_{26}H_{33}NO_6$.it is chemically called as diethyl 2,6-dimethyl-4-[2-[(*E*)-3-[(2-methylpropan-2-yl) oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate.[4]

Figure1: Chemical Structure of Lacidipine

Experimental Work

2.   Materials and Methods

Lacidipine pure sample was gifted from the Micro labs Bangalore. all the polymers like PEG – 6000, PEG – 4000, was purchased from Qualikems fine chem. Pvt. Ltd., Vadodara. The chemicals and solvents Methanol, Anhydrous di sodium hydrogen phosphate, SLS, Ortho-Phosphoric acid were purchased from the Loba chem limited. All the instruments were used in the work are calibrated.

Methods:[7-10]
Preformulation studies
Preformulation study is defined as "investigation of physical and chemical properties of the drug substance alone and combined with the excipients". Preformulation studies are the first step in the rational development of dosage form of drugs. It involves the application of biopharmaceutical principles to the physicochemical parameters of the drug with the goal of designing an optimum delivery system that is stable, bioavailable and can be mass produced.

Melting point by capillary tube method
The melting point of Lecidipine was determined by the capillary tube method. A sufficient quantity of Lecidipine powder was filled into the capillary tube to give a compact column of 4-6 mm in height. The tube was introduced in an electrical melting point apparatus and the temperature was raised. The melting point was recorded, which is the temperature at which the last solid particle of Lecidipine in the tube passed into liquid phase

Drug-Excipient Compatibility Studies
The drug and excipients selected for the formulation were evaluated for physical and chemical compatibility studies.

Physical compatibility study
The physical compatibility studies were conducted to provide valuable information to the formulator in selecting the appropriate excipients for the formulation. It was done by mixing the drugs and excipients and placed at room temperature, 40°C and 75% RH. Any colour change of the physical mixture was observed visually.

S. NO	INGREDIENTS
1	Drug
2	Drug + PEG 6000
3	Drug + PEG 4000
4	Drug + PEG 6000 + PEG 4000

Table2 Composition of drug and excipients for FTIR spectra

Solubility studies of pure Lecidipine
Preformulation solubility analysis was done, which include the selection of suitable solvent, to dissolve the respective drug. The solubility was done by adding the solute in small incremental amounts to the fixed volume of solvents, after each addition, the system was vigorously shaken and examined visually for the undissolved solute particles. When some

amount of the solute remains undissolved, the total amount added up to the point served as a good and rapid estimate of solubility.

Construction of Standard   Calibration Curve of Lacidipine
Spectrophotometric method for the estimation of Lacidipine by spectrophotometric method
Standard Stock solution: A 1000 µg/ml stock standard solution was prepared by dissolving the 100mg of pure Lacidipine   in small amount of methanol and then make up with Phosphate buffer(ph7.0) with 0.5%SLS up to 100 ml.
Secondary stock solution: From the primary stock solution 10ml was accurately pippetted out and transferred into a standard flask and made up to 100ml using Phosphate buffer(ph7.0) with 0.5%SLS, we get 100µg/ml of stock solution. From that sample prepare 10, 20, 30, 40, 50, 60µg/ml solutions.
The standard calibration curve of Lacidipine yields a straight line, which shows that the drug follows Beer's law in the concentration range of 0.5 to 2.5 µg/ml at 252 nm, a standard graph was plotted by keeping the known concentration on X – axis and obtained absorbance on Y – axis.

Preparation ofLacidipine Solid Dispersion technique[11-18]

Formulation	Drug and Polymer	Drug to polymer ratio	Methods
F1		1:1:1	
F2		1:1:2	
F3		1:1:3	
F4	Lacidipine: PEG6000: PEG4000	1:1:4	Solvent evaporation
F5		1:1:5	
F6		1:1:6	
F7		1:1:7	
F8		1:1:8	

Table 3Preparation of solid dispersion of Lacidipine
Solid Dispersion of Drug: Polymer Ratio 1:1:1(F1) (PEG6000: PEG4000)
500mgof PEG-6000and 0.5 g PEG-4000 was weighed and added to 10ml of methanol and stirred well for 2-3 minutes till it gets dissolved.50mg of Lacidipine was weighed and kept aside. 100 ml beaker was taken and to this mixture of polymers and methanol solution and drug was transferred. This mixture will be stirred for 15- 20minutes until the mixture was dissolved completely. Now this was transferred into a china dish and kept in an incubator at 45^0 c for one day until it was dried completely. After drying this content was removed from China dish and it was packed in polythene sachets and stored in cool and dry place.

Solid Dispersion of Drug: Polymer Ratio 1:1:2(F2) (PEG6000: PEG4000)
500mgof PEG6000and 1 gm of PEG4000 was weighed and added to 10ml of methanol and stirred well for 2-3 minutes till it gets dissolved.50mg of Lacidipine was weighed and kept aside. 100 ml beaker was taken and to this mixture of polymers and methanol solution and drugwas transferred. This mixture will bestirred for 15-20minutes until the mixture was dissolved completely. Now this was transferred into a china dish and kept in an incubator at 45^0 c for one day until it was dried completely. After drying this content was removed from china dish and it was packed in polythene sachets and stored in cool

and dry place.

Solid Dispersion of Drug: Polymer Ratio 1:1:3(F3) (PEG6000: PEG4000)
500mgof PEG6000and 1.5gm of PEG4000 was weighed and added to 10ml of methanol and stirred well for 2-3 minutes till it gets dissolved.50mg of Lacidipine was weighed and kept aside. 100 ml beacker was taken and to this mixture of polymers and methanol solution and drug was transferred. This mixture will be stirred for 15-20minutes until the mixture was dissolved completely. Now this was transferred into a china dish and kept in an incubator at 45^0 c for one day until it was dried completely. After drying this content was removed from China dish and it was packed in polythene sachets and stored in cool and dry place.

Solid Dispersion of Drug: Polymer Ratio 1:1:4(F4) (PEG6000: PEG4000)
500mg of PEG6000 and 2gm of PEG 4000 was weighed and added to 10ml of methanol and stirred well for 2-3 minutes till it gets dissolved.50mg of Lacidipine was weighed and kept aside. 100 ml beaker was taken and to this mixture of polymers and methanol solution and drug was transferred. The mixture will be stirred for 15-20minutes until the mixture was dissolved completely. Now this was transferred into a China dish and kept in an incubator at 45^0 c for one day until it was dried completely. After drying this content was removed from China dish and it was packed in polythene sachets and stored in cool and dry place.

Solid Dispersion of Drug: Polymer Ratio 1:1:5 (F5) (PEG6000: PEG4000)
500mg of PEG6000 and 2.5 gm of PEG 4000 was weighed and added to 10ml of methanol and stirred well for 2-3 minutes till it gets dissolved.50mg of Lacidipine was weighed and kept aside. 100 ml beaker was taken and to this mixture of polymers and methanol solution and drug was transferred. The mixture will be stirred for 15-20minutes until the mixture was dissolved completely. Now this was transferred into a China dish and kept in an incubator at 45^0 c for one day until it was dried completely. After drying this content was removed from China dish and it was packed in polythene sachets and stored in cool and dry place.

Solid Dispersion of Drug: Polymer Ratio 1:1: 6 (F6) (PEG6000: PEG4000)
500mg of PEG6000 and 3 gm of PEG 4000 was weighed and added to 10ml of methanol and stirred well for 2-3 minutes till it gets dissolved.50mg of Lacidipine was weighed and kept aside. 100 ml beaker was taken and to this mixture of polymers and methanol solution and drug was transferred. The mixture will be stirred for 15-20minutes until the mixture was dissolved completely. Now this was transferred into a china dish and kept in an incubator at 45^0 c for one day until it was dried completely. After drying this content was removed from china dish and it was packed in polythene sachets and stored in cool and dry place.

Solid Dispersion of Drug: Polymer Ratio 1:1:7 (F7) (PEG6000: PEG4000)
500mg of PEG6000 and 3.5 gm of PEG 4000 was weighed and added to 10ml of methanol and stirred well for 2-3 minutes till it gets dissolved.50mg of Lacidipine was weighed and kept aside. 100 ml beaker was taken and to this mixture of polymers and methanol solution and drug was transferred. The mixture will be stirred for 15-20minutes until the mixture was dissolved completely. Now this was transferred into a china dish and kept in an incubator at 45^0 c for one day until it was dried completely. After drying this content was removed from china dish and it was packed in polythene sachets and

stored in cool and dry place.

Solid Dispersion of Drug: Polymer Ratio 1:1:8 (F8) (PEG6000: PEG4000)
500mg of PEG-6000 and 4 gm of PEG-4000 was weighed and added to 10ml of methanol and stirred well for 2-3 minutes till it gets dissolved.50mg of Lacidipine was weighed and kept aside. 100 ml beaker was taken and to this mixture of polymers and methanol solution and drug was transferred. The mixture will be stirred for 15-20minutes until the mixture was dissolved completely. Now this was transferred into a China dish and kept in an incubator at 45^0 c for one day until it was dried completely. After drying this content was removed from China dish and it was packed in polythene sachets and stored in cool and dry place.

Evaluation parameters for the solid dispersions for Lecidipine formulations
Drug Content:
The solid dispersion was taken in to a mortar and crushed the powder equivalent to 100mg of drug was transferred to 100ml standard flask. The powder was dissolved and made up to volume with Phosphate buffer pH (7.0) with 0.5% SLS. The sample was mixed thoroughly and filtered through a 0.45μ membrane filter. The filtered solution was diluted suitably and analyzed for drug content by UV- spectrophotometer at a by using Phosphate buffer pH (7.0) with 0.5% of SLS as blank.

In vitro drug release studies:
Dissolution rate was studied by using USP type-II apparatus (USP XXIII Dissolution Test Apparatus at 50 rpm) using 900ml of Phosphate buffer pH (7.0) with 0.5% of SLS as dissolution medium. Temperature of the dissolution medium was maintained at 37.5˚C, aliquot of dissolution medium(5ml) was withdrawn at every 5 min interval and filtered. The absorbance of filtered solution was measured by UV spectrophotometric method at 252 nm and concentration of the drug was determined from standard calibration curve.

Drug Kinetics studies: [19]
The invitro dissolution profile of all batches were fitted to Zero order, first order, Higuchi model and Koresmeyer-Peppas model to ascertain the kinetic modeling of drug release. Correlation coefficient (R^2) values were calculated for linear curves obtained by the regression analysis of the above plot.

- **Zero-order kinetic model** – Cumulative % drug released Vs time.
- **First-order kinetic model** – log cumulative % drug remaining Vs time.
- **Higuchi model** - Cumulative % drug released Vs square root of time.
- **Korsmeyer-Peppas model** - log cumulative % drug released Vs log time.

S. No	Release exponent	Drug transport mechanism	Rate as a function of time
1	0.5	Fickian diffusion	$t^{-0.5}$
2	$0.45 < n = 0.89$	Non -Fickian transport	t^{n-1}
3	0.89	Case II transport	Zero order release
4	Higher than 0.89	Super case II transport	t^{n-1}

Table No.4. Release kinetics data

Stability Studies [20]
The purpose of stability testing is to provide evidence on how the quality of a drug substance or drug products varies with time and the influence of a variety of

environmental factors such as temperature, humidity and light and to establish a retest period for the drug substance or a shelf – life for the drug product and recommended storage conditions as per ICH guidelines. Stability studies on prepared solid dispersion containing best batch F1 was carried out by storing 1gm of solid dispersion placed in a desicater at room temperature for a period of 3 months. The solid dispersions visually examined for any physical change, drug release and drug content were estimated at the end of 3 months.

Table no:5 ICH Stability Studies guidelines

S.NO	Study	Storage Condition	Minimum Time Period
1.	Long term	25ºC+ 2ºC/60 %RH+ 5ºC (or) 30C+2ºC/ 65%RH+5%RH	12 months
2.	Intermediate	30ºC+2ºC/65%RH+5%RH	6months
3.	Accelerated	40ºC +2ºC / 75% RH +5 % RH	6months

3.   Results and Discussion

Reformulation Studies
1.1. Melting point by capillary tube method
Melting point of Lacidipine was observed for quality determination, it matches with standard value and the values are given in Table 9.1.

Drug	Standard value	Experimental value
Lacidipine	174.-175 ºC	175 ºC

Table 6 Melting point of pure drug

Drug-Excipient Compatibility Studies
Physical Compatibility Study

S.No	Drug and Excipient	Initial	At Room Temperature			At 40 oC ±2o and 75 % RH ± 2% (in days)		
			10	20	30	10	20	30
1	Lacidipine	White to off- white crystalline solid Powder	NC	NC	NC	NC	NC	NC
2	PEG 6000	White to off- white solid powder	NC	NC	NC	NC	NC	NC
3	PEG 4000	Creamy white waxy powder	NC	NC	NC	NC	NC	NC
5	Lacidipine +PEG 6000	White crystalline solid	NC	NC	NC	NC	NC	NC
6	Lacidipine + PEG 4000	White waxy powder	NC	NC	NC	NC	NC	NC
7	Lacidipine+ PEG 6000+ PEG 4000	Off white creamy wax powder	NC	NC	NC	NC	NC	NC

*NC-No Change
Table 7 Physical Compatibility of Drug and Excipients

Inference
The Physical compatibility study is shown in table 9.2. The drug and excipient were evaluated for 10, 20 and 30 days at room temperature and at 40˚C±2˚C/75±5% Relative Humidity. There was no change in colour.
Therefore, the drug and excipients are physically compatible with each other. The excipients which are compatible with the drug were selected for the formulation

UV Spectrum:
The UV spectrum if the Lacidipine was run with 200-400nm and the Absorption spectrum was obtained at 252 nm.


Figure2: The UV Spectrum for Lacidipine

Calibration curve for the Lacidipine
The standard calibration graph for the pure drug simvastatin had been carried out using pH 7.0 phosphate buffer. The linearity between the concentration and absorbance had been keenly observed, the value of linearity was found to be $r^2= 0.992$.the data were shown in the table no:8 and the graph was represented in the fig no:4.

S.No	Concentration (mg/ml)	Absorbance at 252 nM
1	0	0
2	0.5	0.162
3	1	0.359
4	1.5	0.561
5	2	0.778
6	2.5	0.979

Table 8 calibration curve values for Lacidipine

Calibration Curve for Lacidipine
$y = 0.3969x - 0.0229$
$R^2 = 0.9983$

Figure 3 Calibration curve for Lacidipine

Drug –Polymer Compatibility Studies By Ftir
The compatibility of the Polymer with the drug had been studied with the help of FTIR, DSC and XRD. The studied showed that there are compatible with each other and shows no significant change in the spectra.

Ftir Studies:
In the FTIR studies the IR peaks of the physical mixture had been compared with the individual excipients were there were no shifts of peaks or appearance of the newer peaks compared with each other, which shows that they are chemically stable and compatible. the results are shown in the table no:9,10,11&12 and fig no:5,6,7&8.
IR spectra of Lacidipine pure drug, F1 Formulation illustrated in Table no: 9 & 12 Figure no:5 &8 Characteristic peaks of Lacidipine at 3550.31 cm^{-1} (O-H stretching), 3469.31 cm^{-1} (alcO-H stretching), 1011 cm^{-1} (C=O stretching), 1043 cm^{-1}(C-O-C bending), 1111.76cm^{-1}(C-O ether bending), were observed.

DSC studies:
The DSC thermogram of the drug in figure 5 depicts a sharp endothermic peak at 186°C corresponding to the melting temperature of lacidipine. Such sharp endothermic peak signifies that drug used was in pure crystalline state[36]. A complete disappearance of the drug melting peak was observed in the physical mixture of solid dispersion F1 as shown in figure 6 and 7 respectively, a fact that agrees with the drug was molecularly dispersed within the solid matrix and also indicate the formation of an amorphous solid mixture.

Drug Content
The Drug content of the Solid dispersion formulations of the Lacidipine of F1 and F8 were calculated. the formulation F1 was shows the 99.87 ± 0.012 than compare with the remaining formulations

S .no	Formulation	%Drug content
1	F1	99.87 ± 0.012
2	F2	98.97 ± 0.024
3	F3	96.98 ± 0.025
4	F4	98.41 ± 0.015
5	F5	97.47 ± 0.045
6	F6	97.14 ± 0.041
7	F7	98.01 ± 0.057
8	F8	96.52 ± 0.012

*Mean ± SD of three values
Table 9: drug content of Lacidipine solid dispersion formulation F1 to F8

In vitro dissolution studies of the formulations F1 – F8

S.No	Time in min	% of Cumulative Dissolution Studies			
		F1	F2	F3	F4
1	0	0	0	0	0
2	5	16.12 ± 0.15	15.14 ± 0.45	13.52 ± 0.85	13.45 ± 0.54
3	10	24.15 ± 0.17	22.13 ± 0.23	21.15 ± 0.45	20.14 ± 0.25
4	20	36.15 ± 0.25	34.15 ± 0.24	33.15 ± 0.24	32.14 ± 0.47
5	30	46.17 ± 0.54	42.14 ± 0.15	41.12 ± 0.54	40.12 ± 0.54
6	40	54.84 ± 0.74	51.25 ± 0.25	50.14 ± 0.23	51.24 ± 0.74
7	60	66.17 ± 0.47	63.14 ± 0.15	62.13 ± 0.14	61.24 ± 0.45
8	90	75.12 ± 0.41	72.15 ± 0.85	71.25 ± 0.47	70.15 ± 0.65
9	120	82.14 ± 0.65	79.12 ± 0.45	78.15 ± 0.46	77.45 ± 0.45
10	130	91.14 ± 0.25	90.15 ± 0.45	91.24 ± 0.54	91.25 ± 0.25
11	140	99.87 ± 0.78	97.45 ± 0.14	95.14 ± 1.24	96.25 ± 0.25

Table 10 Invitrodissolution studies of Lacidipineformulation F1- F4


Figure4 Graphical representation of Invitro dissolution studies of Lacidipine formulation F1- F4

Table 11 Invitro dissolution date of Lacidipineformulation F5- F8

S.No	Time in min	% of Cumulative Dissolution Studies			
		F5	F6	F7	F8
1	0	0	0	0	0
2	5	12.56 ± 0.54	12.17 ± 0.85	12.85 ± 0.54	13.54 ± 0.41
3	10	18.25 ± 0.74	17.54 ± 0.78	18.65 ± 0.24	19.15 ± 0.28
4	20	31.25 ± 0.12	32.45 ± 0.87	30.25 ± 0.56	32.25 ± 0.75
5	30	39.14 ± 0.45	41.15 ± 0.54	43.25 ± 0.15	44.12 ± 0.54
6	40	50.24 ± 0.25	51.24 ± 0.54	53.45 ± 0.56	52. 24 ±0.24

| 7 | 60 | 60.12 ± 0.85 | 61.25 ± 0.54 | 62.15 ± 0.65 | 61.25 ± 0.24 |
8	90	70.15 ± 0.45	72.54 ± 0.47	73.45 ± 0.68	73.15 ± 0.56
9	120	76.45 ± 0.87	80.15 ± 0.85	80.12 ± 0.75	80.14 ± 0.74
10	130	82.74 ± 0.47	89.12 ± 0.63	89.88 ± 0.57	88.14 ± 0.54
11	140	95.48 ± 0.56	96.42 ± 0.54	95.89 ± 0.85	96.14 ± 0.74

Figure 5 In vitro Drug release of the Formulations F5 to F8

The Formulations F1 and F8 were evaluated for the % Drug release using the Dissolution apparatus and sample from the dissolution were collected in time interval of 0 to 140 min, the sample was estimated UV spectroscopy at 252 nm. and the % drug release were tabulated. The formulations F1 and F8 shows the vales were ranging from to the 12.17 to the 99.87. The formulation F1 gives the % Drug release at 140 min as 99.87 ± 0.78 and the F2 formulations gives the values ranging from 97.45 ± 0.14 respectively.

Table 12 Comparative study of the % Drug release of the optimized formulation F1 , Pure drug the marketed formulation

Time (min)	% Drug release of (F1)	% Drug release of pure drug	% Drug release of Marketed product
0	0	0	0
5	16.12 ± 0.15	11.26±0.25	15.42±0.65
10	24.15 ± 0.17	19.21±0.54	21.25±0.78
20	36.15 ± 0.25	33.21±0.54	34.15±0.45
30	46.17 ± 0.54	41.52±.024	45.12±0.56
40	54.84 ± 0.74	53.01±1.24	53.18±0.78
60	66.17 ± 0.47	62.34±0.12	64.85±0.89
90	75.12 ± 0.41	70.12±0.14	72.65±0.87
120	82.14 ± 0.65	79.54±0.58	81.57±0.78
130	91.14 ± 0.25	89.54±0.45	90.87±0.54
140	99.87 ± 0.78	96.82±0.47	98.12±0.12

The % drug release of the formulation F1 Shows the good drug release rate compare with pure drug and marketed formulation (Lacivas ® Sun Pharmaceutical Industries Ltd) the results were tabulated. the % drug release of the F1 formulation give 99.87 ± 0.78 .


Figure 6: % Drug Release of F1 and Pure Drug and Marketed Formulation
Drug Kinetis studies of formulation F1

Table13 Drug kinetic studies of optimised formulation F1

Time (min)	cumulative % drug released	% drug remaining	Square root time	log Cumu % drug remaining	log time	log Cumu % drug released	% Drug released	Cube Root of % drug Remaining (Wt)	Wo-Wt
0	0	100	0.000	0.000	0.000	0.000	100	4.642	0.000
5	16.12	83.88	2.236	1.924	0.699	1.207	16.12	4.377	0.265
10	24.15	75.85	3.162	1.880	1.000	1.383	8.03	4.233	0.409
20	36.15	63.85	4.472	1.805	1.301	1.558	12	3.997	0.645
30	46.17	53.83	5.477	1.731	1.477	1.664	10.02	3.776	0.866
40	54.84	45.16	6.325	1.655	1.602	1.739	8.67	3.561	1.081
60	66.17	33.83	7.746	1.529	1.778	1.821	11.33	3.234	1.408
90	75.12	24.88	9.487	1.396	1.954	1.876	8.95	2.919	1.723
120	82.14	17.86	10.954	1.252	2.079	1.915	7.02	2.614	2.028
130	91.14	8.86	11.402	0.947	2.114	1.960	9	2.069	2.573
140	99.87	0.13	11.832	-0.886	2.146	1.999	8.73	0.507	4.135

Zero Order Kinetics

y = 0.5636x + 12.847
R² = 0.9354

Figure 7 Zero Order Kinetics of the Formulation F1

First order Kinetics

y = 0.0075x + 1.1157
R² = 0.4794

Figure 8 First Order Kinetics of the Formulation F1

Higuchi model drug release

y = 8.0773x + 0.1341
R² = 0.9906

Figure 9 Higuchi Model formulation F1

Korsemyer-peppas model

y = 46.083x - 13.855
R² = 0.93

Figure 10 Kores-Peppas Model formulation F1

Table 14regression values of Lecidipine drug kinetic studies

Order of kinetics	Zero order	First order	Higuchi plot	Kors-peppas Model
Regression value(r2)	0.9354	0.4794	0.9906	0.930

The drug kinetic studies of the formulation F1 follows The Higuchi model is a mathematical model that describes the rate of drug release from an insoluble polymer matrix. It is based on Fickian diffusion and suggests that drug release occurs through diffusion through dispersed vesicles.

Table 15 Stability studies of the optimised formulation F1

S.no.	Characteristics	Initial	At the end of 1 month	At the end of 2 month	At the end of 3 month
1	Physical appearance	White	No Change	No Change	No Change
2	Drug content (%)	99.87%	98.87%	96.75%	94.89%
3	Drug Release at end of 120 min	78.98%	75.54%	73.45%	71.02%

The Accelerated stability studies were carried out as per the ICH Guidelines,(40ºC ±2ºC / 75% RH ± 5 % RH) at the end of 3rd month, the formulation F1 shows no significant change Physical and chemical characteristics of the solid dispersion of the Lacidipine. At the end of 3rd month. The % drug content 94.89 % and In vitro drug release at 120 min was found to be 71.02 %.

4. Discussion

The oral drug delivery is the most prominent, simplest and easiest way of administration of drug. It is estimated that 40 %of new chemical entities being discovered are poorly water soluble. Therefore, enhancement of the solubility is the part of the strategy to improve its bioavailability. Many techniques were used to improve the solubility of the drugs. The aim of works is the enhancement of the solubility of Lacidipine by using of solid dispersion using the solvent evaporating technique. The Preformulation were performed for the Lacidipine like Melting point found to be 175 ºC. The drug and excipient were evaluated for 10, 20 and 30 days at room temperature and at 40˚C±2˚C/75±5% Relative Humidity. There was no change in colour. Therefore, the drug and excipients are physically compatible with each other. The excipients which are compatible with the drug were selected for the formulation. The UV spectrum if the Lacidipine was run with 200-400nm and the Absorption spectrum was obtained at 252 nm. The standard calibration graph for the pure drug simvastatin had been carried out using pH 7.0 phosphate buffer. The linearity between the concentration and absorbance had been keenly observed, the value of linearity was found to be $r^2= 0.9983$. The compatibility of the Polymer with the drug had been studied with the help of FTIR, DSC and XRD. The studied showed that there are compatible with each other and shows no significant change in the spectra. IR spectra of Lacidipine pure drug, F1 Formulation

Shows Characteristic peaks of Lacidipine at 3550.31 cm^{-1} (O-H stretching), 3469.31 cm^{-1} (alcO-H stretching), 1011 cm^{-1} (C=O stretching), 1043 cm^{-1}(C-O-C bending), 1111.76cm^{-1}(C-O ether bending), were observed.The DSC thermogram of the drug in figure 5 depicts a sharp endothermic peak at 186°C corresponding to the melting temperature of lacidipine. Such sharp endothermic peak signifies that drug used was in pure crystalline state. A complete disappearance of the drug melting peak was observed in the physical mixture of solid dispersion F1, a fact that agrees with the drug was molecularly dispersed within the solid matrix and also indicate the formation of an amorphous solid mixture. Crystallinity is indicated by the presence of sharp peaks that are absent in the case of amorphous drugs. In X-ray diffractogram, LCDP shows characteristic peaks at 8.15°, 12.15 °, 18.54 °, 19.75 °, 21.15 °, 22.14 °, 24.12 °, 30.13° ,33.35 °. The Drug content of the Solid dispersion formulations of the Lacidipine of F1 and F8 were calculated. the formulation F1 was shows the 99.87 ± 0.78 than compare with the remaining formulations. The Formulations F1 and F8 were evaluated for the % Drug release using the Dissolution apparatus and sample from the dissolution were collected in time interval of 0 to 140 min, the sample was estimated UV spectroscopy at 252 nm. and the % drug release were tabulated. The formulations F1 and F8 shows the vales were ranging from to the 12.17 to 99.87 . The formulation F1 gives the % Drug release at 120 min as 99.85 ± 0.78 and the F2 formulations gives the values ranging from 97.85 ± 0.84 respectively. The drug kinetic studies of the formulation F1 follows The Higuchi model is a mathematical model that describes the rate of drug release from an insoluble polymer matrix. It is based on Fickian diffusion and suggests that drug release occurs through diffusion through dispersed vesiclesThe Accelerated stability studies were carried out as per the Ich Guidelines,(40°C ±2°C / 75% RH ± 5 % RH) at the end of 3rd month, the formulation F1 shows no significant change Physical and chemical characteristics of the solid dispersion of the Lacidipine. At the end of 3rd month. The % drug content 94.89 % and In vitro drug release at 120 min was found to be 71.02 %.

5. Conclusion

The present study was aimed in developing the solid dispersion studies of combination of the polymers like PEG 6000: PEG 4000 prepared by solvent evaporation technique with ratio of Drug and polymer ratio was 1:1:1. The Lacidipine solid dispersion were evaluated for physicochemical characteristics like drug content and in vitro drug release studies. Form FTIR studies, it concluded that there was no chemical interaction between the drugs and polymers like PEG 6000 and PEG 4000. it can provide promising way to enhance its solubility and dissolution rate. The compatibility of the drug and excipients was confirmed by DSV and XRD analysis which clearly compatibility of the polymer and drug. The optimized formulation F1 was Compared with the marketed formulation the F1 shows the In vitro drug release at 99.87% at 140 min. based on the mathematical models, the concluded that formulation F1, the regression value found to be 0.9906 fitted with Higuchi model followsFickian diffusion and suggests that drug release occurs through diffusion through dispersed vesicles.

6. References

1. Mir KB, Khan NA. Solid dispersion: Overview of the technology. International journal of pharmaceutical sciences and research. 2017 Jun 1;8(6):2378-87.
2. Lewis D, Udupa N, Atin K. Solid dispersions: a review. Pak. J. Pharm. Sci. 2009 Apr;22(2):234-46.

3. Hallouard F, Mehenni L, Lahiani-Skiba M, Anouar Y, Skiba M. Solid dispersions for oral administration: an overview of the methods for their preparation. Current pharmaceutical design. 2016 Sep 1;22(32):4942-58.

4. https://pubchem.ncbi.nlm.nih.gov/compound/Lacidipine

5. Komal, Chandrakant, Jadhav.,Sourabh, Sukumar, Hegaje., Sadhana, Uttam, Jadhav., Rupesh, Sopanrao, Vaidhya., Mayuresh, Ramesh, Redkar. (2022). Formulation and Evaluation of Solid Dispersion of Poorly Soluble Drugs. Asian Journal of Pharmacy and Technology,

6. Maria, Elvina, Tresia, Butar-Butar., Nasrul, Wathoni.,Hestiary, Ratih., Yoga, Windhu, Wardhana. (2023). Solid Dispersion Technology for Improving the Solubility of Antiviral Drugs. Pharmaceutical sciences and research, doi: 10.7454/psr.v10i1.1292

7. Peggy Kostakou, GenovefaKolovou,KatherineAnagnostopoulou, Theodor Theodoridis, VassilikiGalea, Constantinos Mihas, VassilikiChristopoulou- Cokkinou,Dennis V. Cokkinos. Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia**,** Archives of Cardiovascular Disease, 103,26-32, (2010).

8. Nelson VK, Nuli MV, Ausali S, Gupta S, Sanga V, Mishra R, kumarJaini P, Kallam SD, Sudhan HH, Mayasa V, Abomughaid MM. Dietary Anti-inflammatory and Anti-bacterial medicinal Plants and its compounds in Bovine mastitis associated impact on human life: A Comprehensive Review. Microbial Pathogenesis. 2024 May 13:106687.

9. Jeslin D, Prema S, Ismail Y, Panigrahy UP, Vijayamma G, RS C, Deepthi KL, Kumar JP. ANALYTICAL METHOD VALIDATION OF DISSOLUTION METHOD FOR THE DETERMINATION OF% DRUG RELEASE IN DASATINIB TABLETS 20MG, 50MG AND 70MG BY HPLC. Journal of Pharmaceutical Negative Results. 2022 Dec 20:2722-32.

10. Neha Parmar, ArtiBagda , MeghalPatelandSandippatel,formulation strategy for dissolution enhancement of simvastatin,IJPSR (2012), Vol. 3, Issue 10

11. Luhadia and agrawal, IJARPB, 2012; Vol.2 (2): 281-291

12. A.ArunachalamCurrent Pharma Research Vol. 1, Issue 1, October-December 2010

13. RaghavendraRao NG, Ravi Kumar Kota, Setty CM, PurushothamRao K. Formulation and Evaluation Of Fast Dissolving Chlorthalidone Tablets. International journal of pharmacy and pharmaceutical sciences, 1, (2009).

14. Makhija SN, Vavia PR. Controlled porosity osmotic pump-based controlled release system of pseudoephedrine, J. Control. Release, 89, 5–18, (2003).

15. Kumar JP, Ismail Y, Reddy KT, Panigrahy UP, Shanmugasundaram P, Babu MK. PACLITAXEL NANOSPONGES'FORMULA AND IN VITRO EVALUATION. Journal of Pharmaceutical Negative Results. 2022 Dec 20:2733-40.

16. Tanaka N, Imai K, Okimoto K, Ueda S, RintaIbuki Y T, Higaki K and Kimura T. Development of novel sustained-release system, disintegration- controlled matrix tablet (DCMT) with solid dispersion granules of nilcadipine (II): In vivo evaluation. Journal of controlled release 122, 51- 56, (2006).

17. Shah, T. J., Amin, A.F., Parikh, J.R., and Parikh, R.H., (2007) Process optimization and characterization of poloxamer solid dispersions of a poorly water-soluble drug, AAPS PharmSciTech; 8 (2) Article 29.

18. Marabathuni VJ, Dinesh P, Ravikumar R, Yamini P, Kiran PS, Hussain SP, **Rao CM**. Chitosan based sustained release mucoadhesive buccal patches containing amlodipine besylate (AMB). Asian Journal of Research in Pharmaceutical Science. 2017;7(2):97-104.

19. Marabathuni VJ, Bhavani M, Lavanya M, Padmaja K, Madhavi N, Babu P, **Rao CM**. Formulation and evaluation of mouth dissolving Tablets of carbamazepine. Asian

Journal of Pharmacy and Technology. 2017;7(3):137-43.

20. Jhansi Priya MV, Prasada Rao CM. Formulation Development & Invitro Evaluation Of Felbamate Nanosuspensions By Using Anti Solvent Precipitation And Ultrasonic Method. Journal of Advanced Zoology. 2024 Jul 1;45(3).